Uso de contraceptivos
1. VOLIBRIS (ambrisentana). Bula do produto.
2. SPENCE, R. et al. Pharmacokinetics and safety of ambrisentam in combination with sildenafil in healthy volunteers. J Clin Pharm, 48:1451-59, 2008.
3. HOEPER, M. et al. Goal-oriented treatment and combination therapy for pulmonar arterial hypertension who discontinued bosentan or sitexsentan due to liver function test abnormalities. European Respiratory Journal, 26(5):858-863, 2005.
4. HARRISON, B. et al. Omeprazole has no clinically relevant effect on the pharmacokinetics of ambrisentan. Am J Respir Crit Care Med, 179:3348, 2009.
5. HARRISON, B. et al. Effects of rifampicin(rifampin) on the pharmacokinetics of ambrisentan in healthy subjects: a single- sequence, open-label study. Clin Drug Investig, 30(12):875-885, 2010.
6. WALKER, G. et al. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br J Clin Pharm, 67: 527-534, 2009.
7. SPENCE, R. et al. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci, 98(12): 4962-4974, 2009.
8. SPENCE, R. et al. Effect of Steady-State Ambrisentan on ambrisentan on the PK of a single dose of the oral contraceptive norethindrone in healthy patients. Clin Drug Invest, 30(5): 313-324, 2011.
9. HARTMAN, J. et al. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol, 88: 682-691, 2010.